Emmaus Life Sciences, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced attendance at the following conferences during National Sickle Cell Awareness Month in September:
Emmaus management will present to the investment community at the 4th Annual Sickle Cell Disease Therapeutics Conferences at The Four Seasons Hotel in New York City on September 3 at 3:10 p.m. Eastern Time.
Emmaus will also present at the 8th Annual International Partnering Conference taking place from September 15-17 at the Boston Marriott Copley Place in Boston.
The company is also attending the 43rd Annual Sickle Cell Disease Association of America Convention from September 23-26 at the Hilton Baltimore in Baltimore.
About Emmaus Life Sciences
Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The therapy has Orphan Drug designation in the U.S. and Europe and Fast Track designation from the FDA.
For more information, please visit www.emmauslifesciences.com.
Contacts:
Media:
Lori Teranishi for Emmaus Life Sciences, Inc.
510-290-6160
lteranishi@iq360inc.com
Investors:
Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com